Encouraging trial results from Anavex

Recent positive results from biotech company Anavex Life Sciences have shown that when treated with their experimental drug, blarcamesine, individuals with Parkinson’s dementia had significant improvements in both motor and cognitive symptoms.


The Anavex results

This week some encouraging clinical trial results were announced by a biotech firm called Anavex Life Sciences. The company had been testing their lead experimental therapy – a Sigma-1 receptor agonist called ANAVEX2-73 (also known as blarcamesine) – in 132 people with Parkinson’s disease dementia over a 14 week period. The […]


EJS-ACT PD

This week an announcement was made regarding The Edmond J. Safra Accelerating Clinical Treatments for Parkinson’s Disease (EJS-ACT PD) Initiative. It is hoping to revolutionise the way clinical trials for potentially disease-modifying drugs for Parkinson’s are conducted. The project is focused on the setting up a multi-arm, multi-stage (MAMS) platform for […]


Improving Parkinson’s Trials: A Delphi Study

Under the visionary leadership of Dr Camille Carroll at the University of Plymouth, Cure Parkinson’s has been supporting an exploratory study at the University of Plymouth to understand the best way of improving clinical trials in order to speed up the development of new treatments…


Fundraising news

Team 144 walk historic bus route for Cure Parkinson’s

A team of incredible supporters from Bromsgrove has taken on the 25-mile long, locally iconic 144 bus route on foot. They have raised over £1950 for our research into a cure for Parkinson’s. At 9am on 30 May, Sophia Harley, Becki Harley, Bryony Billingham, James…